Use of Empagliflozin in Patients with Hypertrophic Cardiomyopathy

Mateusz Spiewak

Prod dr hab. n. med. Mateusz Śpiewak

Project leader

Project value
Project value
Value of the Funding


The project is funded by:
Medical Research Agency

Competition: ABM/2020/1
Project Number:

Project Name:

Use of Empagliflozin in Patients with Hypertrophic Cardiomyopathy

Project Description:

Hypertrophic cardiomyopathy (HCM) is the most common genetically conditioned disease of the heart muscle. Classically, the frequency of this disease was estimated at 1:500 people, but it is probably higher and is about 1:200 cases. In Poland, this equates to 76,000 to 190,000 people.

HCM is asymptomatic in some people. In others, it is associated with progressive diastolic dysfunction of the left ventricle due to hypertrophy and fibrosis of the myocardium, ultimately resulting in systolic dysfunction and progressive heart failure. Both preserved and reduced ejection fraction heart failure inevitably relate to impaired physical capacity, often affecting young, professionally and socially active individuals. An additional significant problem in patients with hypertrophic cardiomyopathy is rhythm disorders leading to an increased risk of sudden death.

Currently, for patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction qualifying for surgical treatment, there is no treatment to halt disease progression.

The aim of the project is to find a therapeutic solution for a condition for which standard medicine has not yet offered satisfactory solutions.

Empagliflozin is a drug registered for the treatment of diabetes. In studies in patients with type 2 diabetes and high cardiovascular risk, the use of empagliflozin was associated with a significant reduction in mortality and hospitalizations due to heart failure. Similar beneficial effects (reduction in cardiovascular mortality, reduction in the number of hospitalizations due to heart failure) were observed in patients with heart failure with impaired left ventricular systolic function, and the beneficial effects of treatment were not dependent on the presence of diabetes (i.e., beneficial effects were also observed in patients without diabetes).

The study, led by the National Institute of Cardiology, the leading unit in Poland specializing in diagnosing and treating patients with HCM, will be implemented in cooperation with the Medical University of Bialystok, as well as with foreign partners: Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland in Kuopio, and the Department of Cardiology, VU University Medical Center in Amsterdam.

The study is funded by the state budget from the Medical Research Agency, Poland, Project Number: 2020/ABM/01/00001

logo Medical Research Agency